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Synthetic Inhibitors of Proline-Rich
Ligand-Mediated Protein-Protein Interaction:
Potent Analogs of UCS15A
local function of signaling proteins but could conceiv-
ably trigger dynamic changes in signaling pathways
downstream of the target proteins. In this regard, pro-
tein-kinase inhibitors represent one of the best exam-
ples of signaling proteins against which small molecule
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Kyowa Hakko Kogyo Co., Ltd. inhibitors have been successfully developed [5].
In the mid-1980s, the discovery of potent protein ki-3-6-6 Asahi-cho
Machida-shi, Tokyo 194-8533 nase inhibitors staurosporine and K-252, derived from
microbial products [5–7], attracted much attention from2Pharmaceutical Research Institute
Kyowa Hakko Kogyo Co., Ltd. the pharmaceutical industry and provided the impetus to
initiate studies to develop selective inhibitors of protein1188 Shimotogari
Nagaizumi-cho, Sunto-gun kinases [8, 9]. Our screens of microbial products to iden-
tify anatagonists targeting signal transduction by proteinShizuoka 411-8731
3Department of Applied Chemistry tyrosine kinases resulted in the rediscovery of radicicol
[10, 11] and UCS15A (SI-4228A/Luminacin) [12], whichSchool of Science and Engineering
Waseda University was previously identified as having antifungal and angio-
genesis inhibitory activities [13–16]. UCS15A was identi-3-4-1 Ohkubo
Shinjuku-ku, Tokyo 169-8555 fied as a small molecule inhibitor of Src-signal transduc-
tion using a yeast-based assay, in which inhibitors wereJapan
detected based on their ability to rescue the growth
arrest of yeast, resulting from the overexpression of
activated v-src [12, 17]. Early investigations into theSummary
mode of action of UCS15A revealed that UCS15A dif-
fered from conventional Src inhibitors in that it did notThe proline-rich motif in proteins is known to function
as a ligand sequence that binds to protein modules inhibit the tyrosine kinase activity of v-src, nor did it
alter the stability of v-src by antagonizing the molecularsuch as SH3, WW, and several other protein interaction
domains. These proline-rich ligand-mediated protein- chaperone hsp90 [12]. Further studies revealed that
UCS15A represented the first example of a nonpeptide,protein interactions (abbreviated PLPI) are important
in many signaling pathways that are involved in various small molecule agent capable of disrupting SH3-medi-
ated protein-protein interactions by interacting directlydiseases. Our previous studies showed that UCS15A,
produced by Streptomyces species, inhibited PLPI. Here with proline-rich ligands in target proteins [18]. Src, the
first tyrosine kinase to be identified [19], contains proteinwe report on synthetic analogs of UCS15A that show
more potent activity than UCS15A in inhibiting PLPI. domains that were later identified in a host of other
proteins, including many nontyrosine kinases, and wereA synthetic analog, compound 2c, blocked in vitro PLPI
of Sam68-Fyn-SH3 as well as in vivo PLPI of Grb2- therefore designated Src homology (SH) domains. In
addition to the catalytic tyrosine kinase domain (desig-Sam68 and Grb2-Sos1. Activation of MEK was also
inhibited by compound 2c. Unlike UCS15A, compound nated the SH1 domain), Src also contains two noncata-
lytic domains, designated SH2 and SH3 domains. These2c was an order of magnitude less cytotoxic and did
not cause morphological changes in treated cells. noncatalytic domains were subsequently shown to be
responsible for critical protein-protein interactions in
signal transduction [20, 21], and many subsequent stud-Introduction
ies highlighted their biological importance. Our studies
on UCS15A have shown that the growth arrest-rescueSignal transduction is carried out by networks of signal-
ing molecules that carry signals from the cell surface assay using Src-overexpressing yeast is a productive
method to discover drugs that inhibit protein-proteinto the nucleus and cause diverse cellular responses
interactions [12].including proliferation, differentiation, migration, metab-
Proline-rich ligands recognize and bind to SH3, WW,olism, cytoskeletal reorganization, and transcriptional
and several protein interaction domains [22]. Proline-regulation [1, 2]. These signaling proteins are connected
rich ligand-mediated protein-protein interactions (PLPI)spatiotemporally by sequential protein-protein interac-
have been implicated in various human diseases suchtions between protein modules that determine the speci-
as cancer, allergy, asthma, osteoporosis, and severalficity of these interactions in the transduction of signals
virus-induced pathologies [22–24]. Given the impor-[1, 3]. Since deregulated signal transduction has been
tance of PLPI, there is a great deal of interest in findingimplicated in several human diseases, drugs that regu-
inhibitors of this interaction. Since UCS15A is the firstlate cellular signaling are actively being sought [4]. Such
and only small molecule inhibitor of PLPI thus far identi-drugs would have the potential to not only regulate the
fied, it represents a promising lead compound for the
development of drugs that inhibit PLPI. Given UCS15A’s*Correspondence: sharma_sreenath@guthrie.org
unique ability to disrupt PLPI, we synthesized com-4Present address: Guthrie Research Institute, 1 Guthrie Square,
Sayre, Pennsylvania 18840. pounds that were structurally related to UCS15A and
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analogs was examined at 100 and 300 M, and particu-Table 1. Inhibitory Activity of UCS15A Analogs on PLPI In Vitro
larly potent inhibitors (which abolished this association
Inhibitory Activity (%) completely, even at concentration of 100 M) were eval-UCS15A
analog 20 M 100 M 300 M uated at an even lower concentration of 20 M (Table
1). In most of the derivatives of UCS15A, the C1 aldehydeUCS15A 8 39 100
moiety of UCS15A was modified (Figure 1A). Five of the1a 85 100
six derivatives of UCS15A tested disrupted PLPI in a1b 95 100
1c 15 100 100 dose-dependent manner, albeit with different efficacies
1d 0 0 (Table 1, compounds 1a–1f). Compound 1c, a perace-
1e 80 100 tate derivative of UCS15A, was slightly more efficient
1f 39 100
that UCS15A in inhibiting PLPI, while compound 1d, a2a 45 100 100
methoxime derivative of UCS15A, showed no inhibition2b 0 0
of PLPI even at concentration as high as 300 M (Table2c 72 100 100
2d 32 100 1). Synthetic compounds with partial structures of
2e 13 35 UCS15A, shown in Figure 1B, were examined to discover
the importance of chemical groups neighboring the ben-Percentage of inhibitory activity of UCS15A analogs on the associa-
tion of Sam68C with Fyn-SH3 in vitro. Values shown are averages zene ring of UCS15A. Among five synthetic compounds
of data obtained in three independent experiments. with partial structures of UCS15A, compounds 2a and
2c showed more potent inhibition of PLPI in this system
than UCS15A, while compound 2b did not show any
inhibitory activity even at a concentration as high as 300examined their potential inhibitory activities toward PLPI
M (Figure 1B and Table 1). Compound 2c was the mostboth in vitro and in vivo. These UCS15A derivatives were
potent of the UCS15A analogs analyzed in this study.synthesized from UCS15A that was prepared by fermen-
The only structural difference between compounds 2ctation. In addition, the recently reported total synthesis
and 2b was the presence of an acyl group at the C3and establishment of the absolute structure of UCS15A
position. Modified compounds with partial structures of[25, 26] provided us access to a number of synthetic
UCS15A, compounds 2d and 2e, were examined to bet-small molecules that were related to UCS15A. Our cur-
ter understand the contribution of the methoxy grouprent studies identify essential regions of the chemical
at the C1″ position. Interestingly, C1″ hydroxy com-backbone of UCS15A as well as chemical groups that
pound 2d was similar to UCS15A, while compound 2e,are important for its ability to disrupt PLPI. In addition,
which has a sugar-like moiety at the C1″ position,our studies have identified compound 2c, a “simple ana-
showed reduced activity toward disrupting PLPI. Takenlog” of UCS15A, as the minimal chemical entity responsi-
together, these findings indicate that some UCS15A an-ble for this activity. Compound 2c exhibited enhanced
alogs have potent inhibitory activities on PLPI as as-potency and reduced cytotoxicity compared to the na-
sayed by the in vitro system and that chemical groupstive drug.
surrounding the benzene ring modulate this activity.
Results
Compound 2c Disrupts PLPI between Grb2-Sam68
and Grb2-Sos1 In VivoEffect of UCS15A Analogs on PLPI
by In Vitro Assays In vitro results suggested that compound 2c was the
most potent inhibitor of PLPI in the in vitro system (TableWe previously showed that UCS15A-mediated disrup-
tion of PLPI could be reproduced in an in vitro assay 1). We therefore focused our attention on the activity of
compound 2c in vivo. Previous studies have shown thatsystem consisting of two recombinant proteins, Fyn-
SH3 and Sam68C [18]. Thus, this highly pure in vitro UCS15A disrupted several combinations of proline-rich
mediated interactions [18]. Among them, the associationsystem was used to assay for other inhibitors of PLPI,
since it allowed the direct examination of the interaction. of Grb2 with Sam68 was chosen to study the effect of
UCS15A analogs on PLPI in vivo. In the experimentTo this end, Sam68C protein was incubated with in-
creasing concentrations of each compound (Figure 2 shown in Figure 3A, Grb2 protein was immunoprecipi-
tated from UCS15A- or compound 2c-treated HCT116and Table 1), as detailed in the Experimental Procedures
section. Subsequently, the AC-Fyn-SH3 domain beads cells, and the associated Sam68 protein was examined
by immunoblot analyses with Sam68 antibody. Aswere added to the reaction. Sample processing and
quantitation of binding were determined as detailed in shown previously [18], Sam68 was found to associate
with Grb2 in untreated cells (Figure 3A, lanes 3 andExperimental Procedures.
The dose dependency of UCS15A for disrupting the 4), and UCS15A effectively blocked the Grb2-Sam68
complex in HCT116 cells (Figure 3A, lanes 4–6). Consis-interaction between Sam68C and Fyn-SH3 was exam-
ined in the in vitro system. As shown previously [18], in tent with the in vitro data, compound 2c had a potent
effect on the in vivo Grb2-Sam68 complex, even at con-the absence of UCS15A, Sam68C associated with Fyn-
SH3 and UCS15A inhibited this interaction in a dose- centrations as low as 2 M (Figure 3A, lanes 1–3). Since
the physiological relevance of the Grb2-Sam68 complexdependent manner (Figure 2). UCS15A-related com-
pounds were classified into two categories: derivatives is at present unclear, we also examined the effect of
the drugs on a more established SH3 domain-mediatedof natural UCS15A (Figure 1A) and synthetic compounds
with partial structure(s) of UCS15A (Figure 1B). Based interaction, namely the Grb2-Sos1 complex, in HeLa
cells (Figure 3B). To this end, Grb2 protein was immuno-on these results, the inhibitory activity of all the UCS15A
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Figure 1. Chemical Structure of UCS15A and Analogs
(A) Structures of UCS15A and its derivatives (1a–1f).
(B) Structures of synthetic analogs of UCS15A (2a–2e).
precipitated from UCS15A-, compound 2c-, or com- (Figure 3B, lanes 8–10). These results demonstrated that
compound 2c, the most potent inhibitor of PLPI in vitro,pound 2b-treated HeLa cells, and the associated Sos1
protein was examined by immunoblot analyses with was also effective in vivo. In addition, the fact that com-
pound 2c was able to disrupt PLPI in vivo indicated thatSos1 antibody. As shown previously in HCT116 cells,
Sos1 was found to associate with Grb2 in untreated the drug was capable of permeating cells.
HeLa cells (Figure 3B, lane 1), and both UCS15A and
compound 2c very effectively disrupted the Grb2-Sos1 Compound 2c Inhibits the Activation
of MAPK Kinasecomplex (Figure 3B, lanes 2–4 and 5–7, respectively).
By contrast, compound 2b had no effect on the Grb2- The finding that compound 2c could inhibit the PLPI
between Grb2-Sam68 and Grb2-Sos1 in cells suggestedSos1 complex even at concentration as high as 10 M
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Figure 2. Inhibitory Activity of UCS15A on PLPI In Vitro
GST-Sam68C was added in the absence or presence of the indi-
cated concentrations of UCS15A and incubated for 6 hr at 37C.
Subsequently, Fyn-SH3 AC beads were added to the reactions and
incubated for 12 hr at 4C. Following the incubation, affinity precipi-
tates with Fyn-SH3 AC beads were probed with anti-GST antibody.
To quantitate the inhibitory activities of UCS15A on PLPI, the densi-
ties of both the Sam68C and Fyn-SH3 bands were scanned from
the autoradiogram of the Western blot. Subsequently, the ratio of
the density of the Sam68C and Fyn-SH3 bands was calculated
and compared to the ratio of the two bands in the absence of the
drug (for details, see Experimental Procedures). Each experiment
was repeated three times, and results were expressed as averages
of the data.
the possibility that the drug may exert an effect on sig-
naling pathways downstream of Grb2. Therefore, activa-
tion of MEK, which is regulated in EGF-induced signal-
ing, was chosen as an example of an interaction that
functions downstream of the PLPI of the Grb2-Sos1
complex. In addition, the effect of the drug on MEK
activation was also tested in HCT116 cells that harbor
an activated K-ras gene; therefore, activation of MAP
kinase should be independent of Grb2-Sos1. Previous
Figure 3. Effect of UCS15A, Compound 2c, and Compound 2b onstudies have shown that phosphorylation of serines 217
PLPI In Vivoand 221 in the MEK protein were essential for its kinase
(A) HCT116 cells were treated for 2 hr with the concentrations ofactivity [27, 28]. The effect of compound 2c was tested
UCS15A and compound 2c indicated at the top of each lane. Anti-on the in vivo activation state of MEK in drug-treated
Grb2 immunoprecipitates (IP) were immunoblotted and probed (WB)
HeLa cells stimulated with EGF, or HCT116 cells without with anti-Sam68 antibody.
serum stimulation. Activation status of MEK was assayed (B) HeLa cells were treated for 2 hr with the concentration of
using a phosphospecific antibody for MEK (Ser217/221) UCS15A, compound 2c, and compound 2b indicated at the top of
each lane. Anti-Grb2 immunoprecipitates (IP) were immunoblotted(Figures 4A and 4B). Serine 217/221 was not phosphory-
and probed (WB) with anti-Sos1 antibody. Positions of migration oflated in serum-starved HeLa cells (Figure 4A, lane 1)
Sam68, Sos1, and the heavy chain of immunoglobulin (Ig hc) areand phosphorylated after stimulation with EGF (Figure
indicated to the right of the autoradiograms. Approximate positions
4A, lane 2). UCS15A treatment decreased the EGF- of migration of prestained molecular weight markers are indicated
dependent phosphorylation of serine 217/221 in a dose- in kilodaltons to the left of the autoradiograms.
dependent manner (Figure 4A, lanes 3–5). Under the
same conditions, compound 2c was slightly more effec-
tive at inhibiting the activation of MEK (Figure 4A, lanes that it may have additional point(s) of action downstream
of ras.6–8), while compound 2b did not alter the status of MEK
phosphorylation under the same conditions (Figure 4A,
lanes 9–11). In untreated HCT116 cells, as expected, Compound 2c Is Distinct from UCS15A in Inducing
Morphological Change in CellsMEK was phosphorylated on Ser 217/221 (Figure 4B,
lanes 1 and 2). However, surprisingly, UCS15A treatment Previous studies have shown that UCS15A-treated v-src
3T3 cells exhibited a very characteristic and reversiblealso decreased the phosphorylation of MEK on serine
217/221 in a dose-dependent manner (Figure 4B, lanes morphological change, resulting in more refractile cells
with almost complete disappearance of filopodia [12].3–5). Similarly to HeLa cells, compound 2c more effec-
tively decreased the phosphorylation of MEK at concen- Similarly, treatment of HCT116 cells for 6 hr with UCS15A
resulted in the characteristic refractile morphology at 1trations as low as 1 M. Taken together, these data
suggested that compound 2c prevented activation of M and 5 M without any effect on the viability of the
cells (Figure 5, panels B1 and B2). UCS15A inhibited theMEK. The surprising fact that it did so even in the context
of an activated ras gene (in HCT116 cells) suggested growth of HCT116 cells with an IC50 of 5.8 M after 72
New Inhibitor of Proline-Rich and SH3 Interaction
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thetic compound 2c, with a partial structure of UCS15A,
was the most potent inhibitor of PLPI in both in vitro
and in vivo assays. Both UCS15A and compound 2c,
were capable of inhibiting the activation of MAPK in cells
harboring wild-type or activated ras genes. However,
unlike UCS15A, compound 2c did not induce drastic
morphological changes in treated cells and was less
cytotoxic to cells.
Since UCS15A contains a reactive epoxide group in
the molecule, it might be expected to bind covalently
to proteins through their amino or thiol group [29–31].
Surprisingly, the present study revealed that the epoxide
group of UCS15A did not appear to play a role in dis-
rupting PLPI, since compounds lacking the epoxide
group retained the ability to inhibit PLPI (Figure 1B and
Table 1). It is interesting that compound 1d, the methox-
ime derivative of UCS15A, did not show inhibitory activ-
ity for PLPI, while other derivatives disrupted PLPI with
varying efficiencies (Figure 1A and Table 1).
Interestingly, even compounds with partial structure
of UCS15A effectively inhibited PLPI, with the exception
of compound 2b (Figure 1B and Table 1). This suggested
that the substitution at the C3 position could be impor-
tant for inhibition of PLPI. Moreover, compound 1a, in
which a hydroxy group was substituted for a carbonyl
group, retained blocking activity, suggesting that the
presence of either a carbonyl or hydroxy group at the
C3 position is sufficient for PLPI inhibitory activity. In
addition, compound 2e, in which the methoxy group at
the C1″ position was substituted for a glucose unit,
Figure 4. Effect of UCS15A, Compound 2c, and Compound 2b on drastically reduced the inhibitory activity of PLPI (Figure
the Activation of MEK in HeLa Cells Stimulated with Epidermal
1B and Table 1). This result suggested that the methoxyGrowth Factor and in HCT116 Cells
group at the C1″ position is also important for blocking(A) Serum-starved HeLa cells were treated for 4 hr with the concen-
PLPI, and the presence of bulky groups may interferetrations of UCS15A, compound 2c and compound 2b indicated at
with this function. Consistent with this hypothesis, sev-the top of each lane. Subsequently, the cells were stimulated with
100 ng/ml of EGF for 15 min as indicated at the top of each lane. eral synthetic compounds lacking the bulky sugar-like
(B) HCT116 cells were treated for 2 hr with the concentrations of unit of compound 2e were potent inhibitors of PLPI (Fig-
UCS15A and compound 2c indicated at the top of each lane. Cells ure 1B and Table 1). These results suggested that the
were lysed and 10g of total cellular proteins was analyzed by SDS-
sugar-like structure of UCS15A does not contribute toPAGE, transferred to nitrocellulose membranes, and immunoblotted
its PLPI blocking activity, but may in fact interfere withwith a phosphospecific anti-MEK1/2 antibody (upper panel). The
this activity.membrane from the upper panel was stripped of the antibody probe
and reprobed with anti-MEK1/2 antibody (lower panel). The position Compound 2c was the smallest synthetic analog of
of migration of phospho-MEK1/2 and MEK1/2 is indicated to the UCS15A capable of blocking PLPI both in vitro as well
right of the autoradiograms. as in vivo (Table 1 and Figure 3, respectively). This sug-
gested that compound 2c permeated through cell mem-
branes and exerted its inhibitory effects on the proline-
hr incubation (data not shown). In contrast, HCT116 cells rich-mediated protein-protein complex in vivo. Further
treated with compound 2c for 6 hr appeared almost evidence for the cell permeability of compound 2c
identical to untreated control cells with typical epithelial emerged from the observation that it inhibited MEK ac-
appearance, even at much higher concentrations of 5 tivity in treated cells (Figure 4). While the in vitro system
or even 20 M (Figure 5, panels C1 and C2). Compound consisted of only two recombinant proteins, and it was
2c inhibited the growth of HCT116 cells with an IC50 of both simple and direct to examine the potential of a
87 M after 72 hr incubation (data not shown). Unlike compound for disrupting PLPI, it is necessary to exam-
UCS15A, compound 2c had no effect on the morphology ine the effect of the drug on PLPI in vivo to know its
of v-src-transformed NIH3T3 cells (data not shown). biological efficacy. In this regard, these results suggest
Taken together, these data indicated that compound 2c that compound 2c is promising for its potential thera-
was more selective than UCS15A and did not cause the peutic activity in animal models of disease in which PLPI
morphological changes induced by UCS15A. have been implicated. Surprisingly, compound 2c was
relatively nontoxic (IC50  87 M) despite its ability to
Discussion disrupt PLPI. In this regard, it differed from the parent
compound UCS15A that also disrupted PLPI but was
In the present study, several analogs of UCS15A were quite toxic (IC50  5.8 M).
An intriguing observation was the fact that 2c requiredsynthesized and shown to inhibit PLPI. Of these, the syn-
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Figure 5. Effect of UCS15A and Compound 2c on the Morphology of HCT116 Cells
HCT116 cells were treated for 6 hr with the concentration of each drug shown at the bottom of each panel. (A), untreated; (B), UCS15A treated;
(C), compound 2c treated. Cells were photographed under the microscope at a magnification of 100.
an order of magnitude more drug to exert its effects in which seems to be a scaffolding molecule that interacts
with various components of the MAP kinase cascade,vitro instead of in vivo (mM versus M range). This is
identical to the observation with the parental drug including Raf-1, MEK1/2, and ERK1/2, and is involved in
coordinating the assembly of a multiprotein MAP kinaseUCS15A [18]. In addition to the numerous explanations
that were advanced to account for these differences complex at the cell membrane (reviewed in [34, 35]).
Interestingly, KSR has a proline-rich domain of as yet(for details please see discussion in [18]), an additional
possibility that we can neither confirm or exclude at this unknown function. Another MAP kinase system that is
regulated by a scaffolding complex is the TAK1-TAB1-point is that, in vivo, the drugs (UCS15A and 2c) are
metabolized into a more potent form. Furthermore, our TAB2 scaffolding complex that regulates activation of
p38 MAP kinase (reviewed in [36]). It is therefore possibleprevious results strongly suggested that UCS15A inhib-
ited proline rich-SH3 interaction but did not disrupt pre- that UCS15A and 2c might work at a point downstream
of ras to disrupt MAPK activation, in spite of the cellsexisting proline rich-SH3 complexes [18]. It is therefore
possible that, in vivo, the number of proteins with free having an activated ras gene. While none of the systems
described above involve SH3 domains and are henceproline-rich domains may be far fewer than in the in vitro
situation, which might also account for the differences unlikely targets of UCS15A/2c, one cannot exclude the
possibility that an as yet undiscovered SH3-PLPI inter-observed.
Consistent with the ability of compound 2c to inhibit action downstream of ras is the critical point of action
of 2c. Clearly, this issue is far from resolved and needsPLPI between Grb2 and Sos1, the compound also inhib-
ited the downstream activation of MEK in EGF-stimu- further investigation.
It is interesting that, as opposed to UCS15A, com-lated HeLa cells (Figure 4A). However, simply because
2c reduced Grb2/Sos1 interaction in vivo does not sug- pound 2c did not induce morphological changes in
treated HCT116 cells (Figure 5) or v-src 3T3 cells (datagest direct causality. That the situation is more complex
than heretofore appreciated is highlighted by the fact not shown). Previous studies suggested a relationship
between PLPI and cytoskeletal organization [37, 38].that 2c also inhibited the activation of MEK in HCT116
cells (Figure 4B), a cell line that harbors an activated Our previous studies also showed that UCS15A dis-
rupted the PLPI between the cytoskeletal proteins cor-K-ras gene [32]. This suggests that additional points of
action of 2c may, in fact, be present downstream of ras. tactin and ZO1 [18, 39]. While the reason for the differ-
ence between UCS15A and compound 2c with regardOne possibility is that 2c may be acting directly on the
Raf/MEK complex, which previous studies have shown to their effects on cell morphology is presently unclear,
two hypotheses can be extended to account for theseis mediated in part by a proline-rich sequence in
MEK1/2, albeit not through SH3 domains [33]. Further- differences. One possibility is that compound 2c dis-
rupts a subset of PLPI involved in signal transduction,more, numerous recent studies have suggested that the
linear representation of the Ras-Raf-MEK pathway may whereas UCS15A is a more generalized disruptor of
PLPI that are involved in signal transduction as well asbe an oversimplification and that there are additional
levels of regulation of this pathway that are controlled cytoskeletal organization. The second possibility is that
while both UCS15A and compound 2c disrupt PLPI,by protein-protein interactions. One such regulatory
molecule is the KSR protein (kinase suppressor of ras), UCS15A may have additional as yet unknown activities
New Inhibitor of Proline-Rich and SH3 Interaction
449
Experimental Proceduresthat allow it to cause morphological changes in cells.
The latter possibility would argue that disrupting PLPI
Chemicalsis unrelated to morphological change-inducing activity.
UCS15A was produced by Streptomyces species and purified in
At present, our results cannot distinguish between these our laboratories. Derivatives of natural UCS15A (compounds 1a–1f)
two hypotheses. and related synthetic compounds (compounds 2a–2e) were pre-
pared in our laboratories. Synthetic procedures and analytical dataThese studies suggest the feasibility of performing
for all compounds are described in the Supplemental Data (seestructure-function analysis with UCS15A. Until recently,
http://www.chembiol.com/cgi/content/full/10/5/443/DC1 or write tothese studies were extremely difficult to conduct, given
chembiol@cell.com for a PDF).the difficulty in synthesizing derivatives of UCS15A and
the very large and complex interaction surface between
Reagents and Cell Lines
SH3 domains and their proline-rich domain ligands. McCoy’s 5A modified medium was obtained from GIBCO. EGF was
These studies represent the first steps in this regard purchased from Life Technologies. GST antibody (Santa Cruz) was
purchased as a horseradish peroxidase (HRP) conjugate. Primaryand only became possible following the total synthesis
antibodies used were as follows: anti-Grb2, anti-Sam68, anti-Sos1of UCS15A [25]. Clearly, more detailed structural studies
(rabbit polyclonal; Santa Cruz); anti-MEK, anti-phospho MEK(NMR as well as X-ray crystallographic) will be necessary
[pS217/221] (rabbit polyclonal; NEB). Secondary antibody consisted ofto completely elucidate the mechanism of action of this
anti-rabbit antibody conjugated to HRP (Amersham). Immunopre-
drug. Nonetheless, the results of this study highlight cipitates were collected on protein A/G beads (Santa Cruz). SH3
structural components of UCS15A that are important for agarose conjugates of Fyn corresponding to amino acids 85–139
of mouse Fyn were generated as a GST fusion protein and conju-disrupting PLPI and suggest the possibility that analogs
gated to agarose (AC). Sam68C consisted of GST fused to aminoof UCS15A might be promising leads for the develop-
acids 331–443 of mouse Sam68. Both GST fusion proteins werement of novel drugs for the treatment of various human
purchased from Santa Cruz. The HCT116 cell line was derived fromdiseases in which PLPI are involved.
a human colon cancer, and the HeLa cell line was derived from a
human cervical cancer (American Type Culture Collection).
Significance
Immunoprecipitation and Immunoblotting Analyses
For immunoprecipitation analyses, two-day-old, subconfluent cellsProline-rich ligand-mediated protein-protein interac-
(two 100 mm dishes per treatment) were treated for 2 hr with differenttions (PLPI) play important roles in signaling pathways.
concentrations (ranging from 0 to 10 M) of UCS15A, compoundThese interactions occur between several critical intra-
2c, or compound 2b in DMSO. It was ensured that all samples,cellular proteins involved in various pathologies. There-
including the untreated cell controls, received the same volume of
fore, PLPI can be therapeutic targets, and a search for DMSO. At the end of the treatment period, cells were placed on ice,
inhibitors to disrupt these interactions is ongoing. So scraped, and collected in their own medium. Cell pellets were lysed
by the addition of 1 ml of ice-cold Triton X-100/NP40 lysis bufferfar, only peptide-based inhibitors of these interactions
as described previously [12]. Lysates were clarified by microcentri-have been reported, and the possibility for the devel-
fugation (15,000 rpm for 30 min at 4C). The protein concentrationopment of small molecule, nonpeptide-based inhibi-
of clarified lysates was determined, and equal amounts of total celltors of PLPI is believed to be remote. Our previous
protein were immunoprecipitated overnight with 3 g of the Grb2
studies demonstrated that UCS15A, a natural compound antibody. Immunoprecipitates were collected on protein A/G beads
produced by Streptomyces species, is a novel small (30 l per immunoprecipitation). Beads were washed three times in
lysis buffer, resuspended in 35 l of Laemml’s sample buffer, andmolecule with SH3-mediated interaction-blocking ac-
resolved on 7.5% SDS-polyacrylamide gels. Proteins were trans-tivity. As a first step toward further development, we
ferred to nitrocellulose membranes (Protran; Schleicher andhave tried to investigate the structural moiety of
Schuell), immunoblotted with the indicated antibody, and subjectedUCS15A that is both necessary and sufficient for its
to chemiluminescent detection.
inhibitory activity toward PLPI. The present studies led For the detection of GST fusion proteins, nitrocellulose mem-
to the discovery of compound 2c, a “simple analog” branes were incubated with HRP-conjugated GST antibody (1:1000
dilution) for 4 hr. For the detection of Sam68, Sos1, or MEK proteins,of UCS15A that retained PLPI blocking activity. In
membranes were incubated with the relevant antibody (1:1000 dilu-addition, these studies identified critical regions of
tion) for 2 hr, followed by secondary antibodies (1:4000 dilution).UCS15A that are responsible for its PLPI disrupting
The effect of UCS15A, compound 2c, and compound 2b on theactivity. These findings will contribute to our ability to
activation of MEK in EGF-stimulated HeLa cells was examined as
build agents to block specific PLPI. This is, however, follows. Briefly, a subconfluent 100 mm dish of cells was trypsinized
presently difficult due to the ability of UCS15A and, and plated into a 6 well multiplate. After the cells had adhered and
perhaps, compound 2c as well to inhibit PLPI in a spread on the dish (approximately 6 hr post-plating), cells were
starved in serum-free medium overnight. Serum-starved HeLa cellsbroadly specific manner. In an attempt to generate
were treated with different concentrations of UCS15A, compoundmore specific agents, it would be worth analyzing the
2c, or compound 2b (0, 0.5, 2, and 5 M, respectively) for 4 hr.detailed costructure of proline-rich regions with com-
Subsequently, cells were stimulated with 100 ng/ml of EGF for 15
pound 2c by X-ray crystallography and NMR analyses. min. In the case of HCT116 cells, cells were neither serum starved
Based on these analyses, it should be possible to de- nor serum stimulated. At the end of the treatment period, cells were
sign more potent agents that will enhance the affinity scraped and collected by low-speed centrifugation. Cell pellets were
lysed by the addition of 75 l of ice-cold RIPA lysis buffer as de-and selectivity for blocking specific PLPI. In addition,
scribed previously [12]. Lysates were clarified by microcentrifuga-the structural information described here may be use-
tion (15,000 rpm for 30 min at 4C). A third of each clarified lysatesful for further chemical modifications. The synthetic
(25 l) was mixed with an appropriate volume of 4 Laemmli’ssmall molecule compound 2c represents a significant
sample buffer, boiled for 10 min, and proteins were separated by
step toward development of second-generation drugs electrophoresis on a 10% polyacrylamide gel. Proteins were trans-
that may be clinically useful in the treatment of various ferred to nitrocellulose membranes, which were then blocked in
TBS-TB buffer (Tris-buffered saline containing 0.1% Tween-20 andhuman diseases in which PLPI are implicated.
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3% bovine serum albumin) for 1 hr. Membranes were then incubated 6. Kase, H., Iwahashi, K., Nakanishi, S., Matsuda, Y., Yamada, K.,
Takahashi, M., Murukata, C., Sato, A., and Kaneko, M. (1987).with the primary antibody (rabbit polyclonal anti-MEK [pS217/221] at a
1:1000 dilution) in TBS-TB overnight at 4C. After briefly washing K-252 compounds, novel and potent inhibitors of protein kinase
C and cyclic nucleotide-dependent protein kinases. Biochem.with TBS-T, the filter was incubated with the secondary antibody
(HRP-conjugated rabbit IgG at a 1:4000 dilution) in TBS-TB for 1 hr, Biophys. Res. Commun. 142, 426–440.
7. Nakano, H., Kobayashi, E., Takahashi, I., Tamaoki, T., Kuzuu,followed by chemiluminescent detection. The blot was stripped as
described previously [12] and reprobed with an appropriate primary Y., and Iba, H. (1987). Staurosporine inhibits tyrosine-specific
protein kinase activity of Rous sarcoma virus transforming pro-antibody (rabbit polyclonal anti-MEK) and secondary antibody, fol-
lowed by chemiluminescent detection. tein p60. J. Antibiot. (Tokyo) 40, 706–708.
8. Tamaoki, T., and Nakano, H. (1990). Potent and specific inhibi-
tors of protein kinase C from microbial origin. Biotechnology 8,In Vitro Proline-Rich SH3 Domain Interaction Assay
732–735.To examine the effect of UCS15A-related compounds indicated in
9. Cohen, P. (2002). Protein-kinases-the major drug targets of theFigure 1 on PLPI, an in vitro system consisting of two proteins was
twenty-first century? Nat. Rev. Drug Discov. 1, 309–315.used as described previously [18]. The two proteins used in this in
10. Pillay, I., Nakano, H., and Sharma, S.V. (1996). Radicicol inhibitsvitro system consisted of the recombinant proteins, Sam68C (0.5
tyrosine phosphorylation of the mitotic substrate SAM68 andg per reaction) and Fyn-SH3 AC beads (5 l of resuspended beads
retards subsequent exit from mitosis of src-transformed cells.per reaction). Each reaction was done in 1 ml of binding buffer as
Cell Growth Differ. 7, 1487–1499.described previously [18]. Binding of compounds to Sam68C was
11. Sharma, S.V., Agatsuma, T., and Nakano, H. (1998). Targetingcarried out for 6 hr at 37C. The concentrations of UCS15A ranged
of the protein chaperone HSP90, by the transformation-sup-from 0 to 500 M, and UCS15A-related compounds ranged from 0
pressing agent, Radicicol. Oncogene 16, 2639–2645.to 300 M as indicated in Figure 2 and Table 1. Following binding
12. Sharma, S.V., Oneyama, C., Yamashita, Y., Nakano, H., Suga-of the compound to Sam68C, Fyn-SH3 AC slurry was added to
wara, K., Hamada, M., Kosaka, N., and Tamaoki, T. (2001).the reaction, and protein-protein interaction was allowed to proceed
UCS15A, a non-kinase inhibitor of Src signal transduction. On-overnight at 4C. Subsequently, the beads were washed three times
cogene 20, 2068–2079.in Triton X-100/NP40 lysis buffer, resuspended in 30 l of Laemmli’s
13. Suzuki, M., Kobayashi, I., and Mitsutake, K. (1983). A new antibi-sample buffer, and the proteins were resolved by electrophoresis
otic SI-4228, method for the production and agricultural micro-on 10% SDS-polyacrylamide gels. Separated proteins were trans-
bicide containing the same as an active constituent. Jpn. Kokaiferred to nitrocellulose membranes, immunoblotted with the indi-
Tokkyo Koho 116, 686.cated antibody, and subjected to chemiluminescent detection.
14. Wakabayashi, T., Kageyama-Kawase, R., Naruse, N., Funa-
hashi, Y., and Yoshimatsu, K. (2000). Luminascins: a family ofQuantification of Inhibitory Activity of UCS15A
capillary tube formation inhibitors from Streptomyces sp. II.Analogs on PLPI
Biological activities. J Antibiot. (Tokyo) 53, 591–596.To quantitate the inhibitory activities of UCS15A and related com-
15. Naruse, N., Kageyama-Kawase, R., Funahashi, Y., and Waka-pounds on PLPI, the densities of both the Sam68C and Fyn-SH3
bayashi, T. (2000). Lumimacins: a family of capillary tube forma-bands were scanned (PDI scanner; TOYOBO). Subsequently, the
tion inhibitors from Streptomyces sp. I. Taxonomy, fermenta-ratio of the density of the Sam68C and Fyn-SH3 bands was calcu-
tion, isolation, physico-chemical properties and structurelated and compared to the ratio of the two bands in the absence
elucidation. J Antibiot. (Tokyo) 53, 579–590.of the drug, which served as the baseline (0% of inhibitory activity).
16. Hata-Sugi, N., Kawase-Kageyama, R., and Wakabayashi, T.Each experiment was repeated three times, and results were ex-
(2002). Characterization of rat aortic fragment within collagen
pressed as averages of the data.
gel as an angiogenesis model; capillary morphology may reflect
the action mechanism of angiogenesis inhibitors. Biol. Pharm.
Photomicroscopy Bull. 25, 446–451.
HCT116 cells were plated in 6-well multiplates as described above. 17. Kornbluth, S., Jove, R., and Hanafusa, H. (1987). Characteriza-
Approximately 8 hr after plating, cells were either left untreated or tion of avian and viral p60src proteins expressed in yeast. Proc.
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